16 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 21 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 16, Unknown 2, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Sleep Disorders: new trials by email Literature Review of Sleep Disorders trials Research Report on Sleep Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Not yet recruiting | Pfizer | 258 | 2026-10-19 | 2026-10-19 |
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Recruiting | Pfizer | 258 | 2026-09-17 | 2026-10-13 |
| Z-Drugs for Sleep Disorders in Alzheimer's Disease Zolpidem, Zoplicone, Placebo - Sleep, Sleep Disorders | Phase 3 | Completed | Brasilia University Hospital | 62 | 2016-10-01 | 2020-11-10 |
| Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders NPC-15 - Sleep Disorders, Neurodevelopmental Disorder | Phase 3 | Completed | Nobelpharma | 99 | 2016-06-21 | 2019-04-16 |
| Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders NPC-15 Granules Lower Dose, NPC-15 Granules Higher Dose, NPC-15 Placebo Granule - Sleep Disorders, Autism Spectrum Disorder | Phase 2 / Phase 3 | Completed | Nobelpharma | 196 | 2016-06-16 | 2019-04-16 |
| Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Circadin 2/5/10 mg, Placebo - Sleep Disorders | Phase 3 | Completed | Neurim Pharmaceuticals Ltd. | 125 | 2013-10-01 | 2024-04-23 |
| Mirtazapine for Sleep Disorders in Alzheimer's Disease Mirtazapine - Alzheimer's Disease, Sleep Disorders | Phase 3 | Unknown | Brasilia University Hospital | 30 | 2012-05-01 | 2013-06-04 |
| Trazodone for Sleep Disorders in Alzheimer's Disease Trazodone, Placebo - Sleep, Sleep Disorders | Phase 3 | Completed | Brasilia University Hospital | 40 | 2010-03-01 | 2012-10-15 |
| Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD prazosin, placebo - PTSD, Sleep Disorders | Phase 3 | Completed | VA Office of Research and Development | 304 | 2010-01-06 | 2018-05-01 |
| Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia Pregabalin, Placebo - Fibromyalgia, Sleep Disorders | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 119 | 2009-06-01 | 2021-01-25 |
| Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy BF2.649, Modafinil, Placebo - Narcolepsy, Excessive Daytime Sleepiness | Phase 3 | Completed | Bioprojet | 110 | 2009-05-01 | 2012-06-11 |
| Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer energy-based therapy, sham intervention - Anxiety Disorder, Breast Cancer | Phase 3 | Completed | Virginia Commonwealth University | 161 | 2009-04-01 | 2015-11-23 |
| Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) esmirtazapine - Sleep Initiation and Maintenance Disorders, Mental Disorders | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 184 | 2008-10-07 | 2021-02-02 |
| A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002) Esmirtazapine, Placebo - Sleep Initiation and Maintenance Disorders, Mental Disorders | Phase 3 | Completed | Merck Sharp & Dohme LLC | 460 | 2008-03-04 | 2018-10-02 |
| A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) Esmirtazapine - Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder | Phase 3 | Completed | Merck Sharp & Dohme LLC | 259 | 2008-01-09 | 2021-01-27 |
| Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 Tamoxifen, triptorelin, Exemestane - Breast Cancer, Fatigue | Phase 3 | Completed | ETOP IBCSG Partners Foundation | 86 | 2007-12-01 | 2016-07-25 |
| Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709) Esmirtazapine, Placebo - Insomnia, Sleep Initiation and Maintenance Disorders | Phase 3 | Completed | Merck Sharp & Dohme LLC | 538 | 2007-11-20 | 2018-10-03 |
| A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia Zolpidem MR, Zolpidem - Sleep Initiation and Maintenance Disorders, Sleep Disorders | Phase 3 | Completed | Astellas Pharma Inc | 876 | 2006-02-01 | 2014-08-20 |
| Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients cognitive-behavioral therapy - Sleep Disorders, Kidney Diseases | Phase 3 | Unknown | National Taiwan University Hospital | 30 | 2005-06-01 | 2007-01-09 |
| Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause DVS-233 SR - Menopause, Hot Flashes | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 568 | 2004-09-01 | 2006-05-19 |
Showing 20 of 21. Sign in to see all of them.
Sleep Wake Disorders (21) · Sleep Initiation and Maintenance Disorders (7) · Parasomnias (5) · Dyssomnias (4) · Mental Disorders (4) · Alzheimer Disease (3) · Fatigue (3) · Sleep Disorders, Intrinsic (3) · Apnea (2) · Autism Spectrum Disorder (2) · Breast Neoplasms (2) · Disorders of Excessive Somnolence (2) · Sleep Apnea Syndromes (2) · Angelman Syndrome (1) · Anxiety Disorders (1)
Nervous System Diseases (21) · Neurologic Manifestations (21) · Pathological Conditions, Signs and Symptoms (21) · Signs and Symptoms (21) · Mental Disorders (17) · Sleep Disorders, Intrinsic (8) · Dyssomnias (7) · Central Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Brain Diseases (3) · Dementia (3) · Neoplasms (3) · Neurocognitive Disorders (3) · Tauopathies (3) · Breast Diseases (2)
Mirtazapine (5) · Melatonin (3) · Zolpidem (2) · Cognitive Behavioral Therapy (1) · Gonadotropin-Releasing Hormone (1) · Modafinil (1) · Prazosin (1) · Pregabalin (1) · Tamoxifen (1) · Trazodone (1) · Triptorelin Pamoate (1) · Valeriana extract (1) · exemestane (1) · pitolisant (1)
Merck Sharp & Dohme LLC (4) · Brasilia University Hospital (3) · Nobelpharma (2) · Pfizer (2) · Alliance for Clinical Trials in Oncology (1) · Astellas Pharma Inc (1) · Bioprojet (1) · ETOP IBCSG Partners Foundation (1) · National Taiwan University Hospital (1) · Neurim Pharmaceuticals Ltd. (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · VA Office of Research and Development (1) · Virginia Commonwealth University (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (7) · Brazil (3) · Canada (2) · Finland (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Yushiro Yamashita, MD, PhD (2) · Charles L. Loprinzi, MD (1) · Claudio Bassetti (1) · Deborah McGuire, PhD,RN,FAAN (1) · Einstein F Camargos, MD, MsC (1) · Francisca M Scoralick, MD (1) · Juerg Bernhard, PhD (1) · Kelly-Anne Phillips (1) · Luciana L. Louzada, MD, MsC (1) · Murray A. Raskind, MD (1) · Paul Gringras, PhD (1)
PMID 32351205, PMID 33189083, PMID 21399726, PMID 22232085, PMID 24107292, PMID 24495406, PMID 26435889, PMID 27092785, PMID 29096777, PMID 29414272, PMID 31982581, PMID 32912180, PMID 34635802, PMID 34822113, PMID 34935103, PMID 37651553
2008 (1)